Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

John H Stone, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by John Stone and Paul Monach.
John Stone
Connection Strength
2.773
Paul Monach
  1. Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with ANCA-Associated Vasculitis. ACR Open Rheumatol. 2022 Feb; 4(2):168-176.
    View in: PubMed
    Score: 0.243
  2. Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2019 11; 71(11):1879-1887.
    View in: PubMed
    Score: 0.209
  3. Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res (Hoboken). 2017 07; 69(7):1004-1010.
    View in: PubMed
    Score: 0.179
  4. Case 6-2017. A 57-year-old woman with fatigue, sweats, weight loss, headache, and skin lesions. N Engl J Med. 2017 Feb 23; 376(8):775-786.
    View in: PubMed
    Score: 0.175
  5. Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets. Arthritis Rheumatol. 2016 12; 68(12):2945-2952.
    View in: PubMed
    Score: 0.172
  6. Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2015 Feb; 67(2):535-44.
    View in: PubMed
    Score: 0.151
  7. Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis. Arthritis Rheum. 2012 Oct; 64(10):3463-71.
    View in: PubMed
    Score: 0.129
  8. Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Ann Rheum Dis. 2013 Aug; 72(8):1342-50.
    View in: PubMed
    Score: 0.128
  9. Circulating angiopoietin-2 as a biomarker in ANCA-associated vasculitis. PLoS One. 2012; 7(1):e30197.
    View in: PubMed
    Score: 0.123
  10. Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2011 Dec; 63(12):3988-97.
    View in: PubMed
    Score: 0.122
  11. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15; 363(3):221-32.
    View in: PubMed
    Score: 0.111
  12. Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis. JCI Insight. 2021 11 22; 6(22).
    View in: PubMed
    Score: 0.061
  13. Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis. Front Immunol. 2020; 11:2053.
    View in: PubMed
    Score: 0.056
  14. Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2019 11; 71(11):1888-1893.
    View in: PubMed
    Score: 0.052
  15. The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. J Autoimmun. 2019 12; 105:102302.
    View in: PubMed
    Score: 0.052
  16. Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis. Arthritis Rheumatol. 2018 12; 70(12):2077-2086.
    View in: PubMed
    Score: 0.049
  17. Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2018 07; 70(7):1114-1121.
    View in: PubMed
    Score: 0.047
  18. Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. Rheumatology (Oxford). 2018 04 01; 57(4):639-650.
    View in: PubMed
    Score: 0.047
  19. The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. Clin J Am Soc Nephrol. 2018 02 07; 13(2):251-257.
    View in: PubMed
    Score: 0.047
  20. Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. Am J Nephrol. 2017; 46(3):231-238.
    View in: PubMed
    Score: 0.045
  21. Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. Arthritis Rheumatol. 2017 05; 69(5):1054-1066.
    View in: PubMed
    Score: 0.044
  22. Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis. Clin Exp Immunol. 2017 04; 188(1):174-181.
    View in: PubMed
    Score: 0.044
  23. Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2017 01; 69(1):185-193.
    View in: PubMed
    Score: 0.043
  24. The Pharmacogenomic Association of Fc? Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2017 01; 69(1):169-175.
    View in: PubMed
    Score: 0.043
  25. Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3. Arthritis Rheumatol. 2016 07; 68(7):1700-10.
    View in: PubMed
    Score: 0.042
  26. Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. Anal Chem. 2016 06 21; 88(12):6317-25.
    View in: PubMed
    Score: 0.042
  27. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis. 2016 Jun; 75(6):1166-9.
    View in: PubMed
    Score: 0.040
  28. Neutrophil-Related Gene Expression and Low-Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2015 Jul; 67(7):1922-32.
    View in: PubMed
    Score: 0.039
  29. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Arthritis Rheumatol. 2015 Jun; 67(6):1629-36.
    View in: PubMed
    Score: 0.039
  30. Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2014 Nov; 66(11):3151-9.
    View in: PubMed
    Score: 0.037
  31. Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthritis Rheum. 2013 Sep; 65(9):2457-68.
    View in: PubMed
    Score: 0.034
  32. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2013 Sep; 65(9):2441-9.
    View in: PubMed
    Score: 0.034
  33. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013 Aug 01; 369(5):417-27.
    View in: PubMed
    Score: 0.034
  34. Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken). 2012 Feb; 64(2):273-9.
    View in: PubMed
    Score: 0.031
  35. IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. Proc Natl Acad Sci U S A. 2011 Dec 20; 108(51):20736-41.
    View in: PubMed
    Score: 0.030
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.